. Author manuscript; available in PMC: 2006 May 17.

Published in final edited form as: Arch Ophthalmol. 2001 Oct;119(10):1417–1436. doi: 10.1001/archopht.119.10.1417

Table 8.

Effect of Treatment on Risk of Development of Neovascular AMD and Central Geographic Atrophy^*

	Neovascular AMD (n = 2556)		Central Geographic Atrophy (n = 2124)
Treatment	OR (99% CI)	PValue	OR (99% CI)	PValue
Antioxidants vs no antioxidants	0.83 (0.64–1.07)	.06	0.88 (0.62–1.26)	.37
Zinc vs no zinc	0.76 (0.58–0.98)	.005	0.84 (0.59–1.21)	.22
Antioxidants vs placebo	0.79 (0.56–1.13)	.09	0.80 (0.48–1.32)	.25
Zinc vs placebo	0.73 (0.51–1.04)	.02	0.76 (0.46–1.27)	.17
Antioxidants + zinc vs placebo	0.62 (0.43–0.90)	.001	0.75 (0.45–1.24)	.13
Total No. of participants with events	592		257

Age-related macular degeneration (AMD) Category 3 and 4 participants. Unadjusted analysis, by repeated-measures logistic regression. Neovascular AMD indicates photocoagulation or other treatment for choroidal neovascularization, nondrusenoid retinal pigment epithelial detachment, serous or hemorrhagic retinal detachment, hemorrhage under the retina or pigment epithelium, or subretinal fibrosis; for central geographic atrophy, eyes of participants with prior neovascular AMD are excluded. OR indicates odds ratio; CI, confidence interval. P≤.01 is considered statistically significant.